Neuroone Medical Technologies (NMTC) investor relations material

Strategic focus and technology overview

• Focuses on transforming lives through innovative devices for neurological diseases, especially epilepsy and chronic pain.

• Four devices have received FDA 510(k) clearance, with strong success in regulatory approvals.

• Leverages thin film and wire-like electrode technology for less invasive procedures and dual diagnostic/therapeutic use.

• Partnerships with Mayo Clinic and Zimmer Biomet support development and commercialization; international expansion planned after ISO 13485 clearance.

• Commercial presence currently in the U.S., targeting underserved epilepsy and trigeminal neuralgia markets.

Product pipeline and clinical impact

• OneRF Ablation System enables single-procedure treatment for epilepsy, reducing hospitalizations and improving patient experience.

• Trigeminal neuralgia device allows precise, single-placement ablation, with all 16 treated patients pain-free to date.

• BVNA spinal cord stimulation and drug delivery systems are in development, targeting fast-growing lower back pain and advanced brain therapies.

• Drug delivery technology enables targeted infusion through the blood-brain barrier, supporting gene and cell therapy studies.

• Spinal cord stimulation electrode offers customizable, percutaneous therapy with energy conservation benefits.

Financial position and growth outlook

• Debt-free with healthy margins and year-over-year revenue growth, supported by Zimmer Biomet partnership.

• Cash runway extends through fiscal year 2026, with monthly cash burn of $700,000–$750,000.

• Additional non-dilutive capital opportunities and ATM facility available for funding needs.

• Trigeminal neuralgia and BVNA represent upside not yet factored into current financial plans.

• Currently covered by three analysts, with further upside expected from new device launches and market expansion.